Planchard D, Garassino MC, Paz-Ares L, Faivre-Finn C, Spira A, Gu Y, Wadsworth C, Whiteley J, Scott M, Boothman AM, Ratcliffe M, Walker J, Dennis PA, Antonia SJ
Prevalence of programmed death ligand-1 (PD-L1) by demographic, disease and sample characteristics in unresectable, stage III NSCLC (PACIFIC).
Annals of oncology : official journal of the European Society for Medical Oncology, 2019-04-01.